Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM9X0G)

• Drug Name: 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info
• Synonyms: 4-(4-Butylpiperidin-1-yl)-1-o-tolylbutan-1-one; AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9948320
  TTD Drug ID: DMM9X0G

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[4]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[5]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[5]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[6]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[7]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[8]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[9]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[10]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[11]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[11]

Drug(s) Targeting Neurotensin receptor type 1 (NTSR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclinertant	DMBIO6E	Inflammatory bowel disease	DD72	Phase 2/3	[12]
ABS-212	DMZ52P6	Pain	MG30-MG3Z	Terminated	[13]
CGX-1160	DMADYF7	Acute or chronic pain	MG30-MG31	Terminated	[14]
JMV458	DMC1ARG	Discovery agent	N.A.	Investigative	[15]
Neurotensin(8-13)	DMOBU62	N. A.	N. A.	Investigative	[16]
JMV449	DME9GF8	Discovery agent	N.A.	Investigative	[17]
SR48527	DMUHQS9	Discovery agent	N.A.	Investigative	[18]
HBN-2	DM5VDU2	Neurological disorder	6B60	Investigative	[19]
[3H]meclinertant	DMEX6GT	Discovery agent	N.A.	Investigative	[18]
H-Arg-Arg-Pro-Tyr-Ile-Aac-OH	DMENVKA	Discovery agent	N.A.	Investigative	[20]

Drug(s) Targeting Gastrin/cholecystokinin type B receptor (CCKBR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pentagastrin	DMRCLZB	Diagnostic imaging	N.A.	Approved	[21]
Ceruletide	DM2WE5K	Caerulein stimulated gastric and pancreatic secretion	5A4Y	Approved	[22]
GASTRAZOLE	DMO3ITF	Duodenal ulcer	DA63	Phase 3	[23]
Dexloxiglumide	DM52HUD	Pancreatic malfunction	DC30-DC3Z	Phase 2	[24]
Spiroglumide	DM7NJWY	Stomach disease	DA43-DA4Y	Phase 2	[25]
TT-223	DMCDMFP	Type-1 diabetes	5A10	Phase 2	[26]
Z 360	DM2M80G	Discovery agent	N.A.	Phase 2	[27]
S-0509	DM4KWEF	Ulcerative colitis	DD71	Phase 2	[28]
YF-476	DM54MAJ	Stomach ulcer	DA60.Z	Phase 2	[29]
Itriglumide	DM5UFRO	Anxiety disorder	6B00-6B0Z	Phase 2	[30]

Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[31]
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[32]
Connexyn	DMF29Q5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[33]
Guanfacine	DMPN5IH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[34]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[35]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[36]
DSP-1200	DM4WSHG	Depression	6A70-6A7Z	Phase 1	[8]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[37]
NMI-870	DMU596F	Sexual dysfunction	HA00-HA01	Discontinued in Phase 2	[38]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[39]

Drug(s) Targeting Muscarinic acetylcholine receptor M4 (CHRM4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[40]
Methacholine Chloride	DMGS4QH	Asthma	CA23	Approved	[41]
Tropicamide	DM1D90W	Mydriasis	LA11.62	Approved	[42]
Diphenidol	DMHPWOM	Nausea	MD90	Approved	[43]
A-987306	DMU34BK	Discovery agent	N.A.	Investigative	[44]
ISOCLOZAPINE	DM52CPU	Discovery agent	N.A.	Investigative	[45]
FLUMEZAPINE	DMW0HOG	Discovery agent	N.A.	Investigative	[46]
ISOLOXAPINE	DMH1BN4	Discovery agent	N.A.	Investigative	[47]
Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester	DMVEH40	Discovery agent	N.A.	Investigative	[41]
GNF-PF-5618	DMT8VUS	Discovery agent	N.A.	Investigative	[48]

Drug(s) Targeting Norepinephrine transporter (NET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[49]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[50]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[51]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[49]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[52]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[53]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[54]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[53]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[55]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[56]

Drug(s) Targeting Dopamine D1 receptor (D1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenyltoloxamine	DMKAEQW	Allergy	4A80-4A85	Approved	[57]
Pergolide	DM14MAE	Parkinson disease	8A00.0	Approved	[5]
Methylergonovine	DMBEX4O	Spontaneous abortion	JA00.0	Approved	[58]
Fenoldopam	DMFAOKP	Hypertension	BA00-BA04	Approved	[59]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[60]
Ecopipam	DMS9R43	Cocaine addiction	6C45.2	Phase 3	[61]
DAS-431	DMM3BPL	Dementia	6D80-6D86	Phase 2	[62]
Dihydrexidine	DMACPQO	Psychotic disorder	6A20-6A25	Phase 1/2	[63]
Lu AF28996	DMY572G	Parkinson disease	8A00.0	Phase 1	[64]
BAM-1110	DMPMKUF	Parkinson disease	8A00.0	Discontinued in Phase 2	[65]

Drug(s) Targeting Endothelin A receptor (EDNRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[5]
Ambrisentan	DMD1QXW	Pulmonary arterial hypertension	BB01.0	Approved	[11]
Macitentan	DMP79A1	Cardiovascular disease	BA00-BE2Z	Approved	[4]
Sparsentan	DMMP51W	IgA nephropathy	MF8Y	Approved	[66]
LU302146	DMMJVXZ	Pulmonary hypertension	BB01	Approved	[67]
Atrasentan	DMM74PK	Diabetic nephropathy	GB61.Z	Phase 3	[68]
Clazosentan	DMQSBX4	Cerebral vasospasm	BA85.Z	Phase 3	[69]
PF-1228305	DMS1EQ7	Pulmonary hypertension	BB01	Phase 3	[70]
Darusentan	DMN8DQH	Hypotension	BA20-BA21	Phase 3	[71]
BQ-123	DM0MO8I	Pulmonary arterial hypertension	BB01.0	Phase 2	[72]

Drug(s) Targeting Serotonin transporter (SERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[49]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[50]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[5]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[4]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[73]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[52]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[53]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[5]
Nortriptyline	DM4KDYJ	Depression	6A70-6A7Z	Approved	[5]
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[5]

Drug(s) Targeting Muscarinic acetylcholine receptor M1 (CHRM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[40]
Fesoterodine fumarate	DM13495	Overactive bladder	GC50.0	Approved	[74]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[75]
Clidinium	DMUMQZ0	Abdominal stomach pain	DD91.4	Approved	[76]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[77]
Oxyphenonium	DMMQHOZ	Visceral spasms	MD81.4	Approved	[78]
Benztropine	DMGZOVN	Parkinson disease	8A00.0	Approved	[79]
Glycopyrrolate	DM2M3ZA	Anaesthesia	9A78.6	Approved	[80]
Pirenzepine	DMP6M1N	Peptic ulcer	DA61	Approved	[81]
Cycrimine	DM8C43Q	Parkinson disease	8A00.0	Approved	[82]

Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methamphetamine	DMPM4SK	Anxiety		Approved	[83]
Propericiazine	DME9JNL	Psychiatric disorder	6E8Z	Approved	[84]
Methoxamine	DMF5XQH	Hypertension	BA00-BA04	Approved	[85]
Phendimetrazine	DM6TS1N	Obesity	5B81	Approved	[86]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[36]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[87]
Sunepitron	DM6M8ZX	N. A.	N. A.	Discontinued in Phase 3	[88]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[37]
SOU-001	DMPAEK5	Urinary incontinence	MF50.2	Discontinued in Phase 2	[89]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[90]

Drug(s) Targeting Acetylcholinesterase (AChE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[91]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[92]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[93]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[94]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[95]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[96]
YM443	DMNZCI1	Functional dyspepsia	DD90.3	Approved	[74]
Ambenonium	DMOP0BL	Myasthenia gravis	8C6Y	Approved	[97]
Demecarium bromide	DMAYEU1	Open-angle glaucoma	9C61	Approved	[98]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[99]

Drug(s) Targeting Glucocorticoid receptor messenger RNA (GCR mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vamorolone	DM047HI	Duchenne muscular dystrophy	8C70.1	Approved	[100]
CORT125281	DMHBOUX	Prostate cancer	2C82.0	Phase 2	[9]
ISIS-GCCR	DMICMNU	Diabetic complication	5A2Y	Phase 2	[101]
ORIC-101	DMR12S0	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
AZD9567	DMAXHC0	Rheumatoid arthritis	FA20	Phase 1	[100]
A-348441	DM25CBW	Type-2 diabetes	5A11	Phase 1	[102]
(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE	DMTPQ84	Discovery agent	N.A.	Investigative	[103]
deoxycorticosterone	DMW6YLS	Discovery agent	N.A.	Investigative	[103]
LGD-5552	DM67KWM	Discovery agent	N.A.	Investigative	[104]
AL-43	DMLEDHR	Discovery agent	N.A.	Investigative	[105]

Drug(s) Targeting Histamine H2 receptor (H2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[106]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[107]
Famotidine	DMRL3AB	Gastric ulcer	DA60	Approved	[107]
Nizatidine	DMGFV3Z	Acid-reflux disorder	DA22	Approved	[108]
Betazole	DMUFGAY	Gastric secretory disorder	DD90	Approved	[109]
Ebrotidine	DMV5KR3	Duodenal ulcer	DA63	Withdrawn from market	[110]
Pibutidine	DMXSTRM	Ulcerative colitis	DD71	Discontinued in Phase 3	[111]
Osutidine	DMN7TL8	Duodenal ulcer	DA63	Discontinued in Phase 3	[112]
KU-1257	DMZMFX6	Duodenal ulcer	DA63	Discontinued in Phase 3	[113]
Lavoltidine	DMTY5VE	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[114]

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[115]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[116]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[117]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[118]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[119]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[120]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[121]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[121]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[121]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[121]

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[115]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[122]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[123]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[4]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[124]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[125]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[126]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[127]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[128]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[60]

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[129]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[130]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[131]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[132]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[133]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[134]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[135]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[136]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[132]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[132]

Drug(s) Targeting Adrenergic receptor beta-1 (ADRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[137]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[138]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[139]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[140]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[140]
Metoprolol	DMOJ0V6	Acute coronary syndrome	BA41	Approved	[140]
Timolol	DM3NXRU	High blood pressure	BA00	Approved	[141]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[142]
Betaxolol	DM6EUL5	Hypertension	BA00-BA04	Approved	[143]
Sotalol	DML60TN	Sinus rhythm disorder	BC9Y	Approved	[144]

Drug(s) Targeting Muscarinic acetylcholine receptor M2 (CHRM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[40]
Methacholine Chloride	DMGS4QH	Asthma	CA23	Approved	[41]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[75]
Methylscopolamine	DM5VWOB	Peptic ulcer	DA61	Approved	[145]
Gallamine Triethiodide	DMPO0MS	Stabilize muscle contraction	FB3Z	Approved	[146]
FP-1097	DMC1F2T	Urinary incontinence	MF50.2	Phase 2	[147]
PSD-506	DMT0KB1	Overactive bladder	GC50.0	Discontinued in Phase 2	[148]
Otenzepad	DMRXHAC	Heart failure	BD10-BD13	Discontinued in Phase 2	[149]
SCH-211803	DM92E0W	Parkinson disease	8A00.0	Discontinued in Phase 1	[150]
Alvameline	DMLN0Y5	Alzheimer disease	8A20	Terminated	[151]

Drug(s) Targeting Substance-P receptor (TACR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[152]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[11]
Rolapitant	DM8XP26	Chemotherapy-induced nausea	MD90	Approved	[153]
Netupitant	DMEKAYI	Chemotherapy-induced nausea	MD90	Phase 3	[153]
Serlopitant	DM5VH6U	Prurigo nodularis	EC91.0	Phase 3	[154]
LY-686017	DM7WORZ	Atopic dermatitis	EA80	Phase 3	[155]
Elinzanetant	DMC6EFI	Hot flushes	GA30	Phase 3	[156]
CP-122721	DMSWLM5	Major depressive disorder	6A70.3	Phase 2	[157]
FR139317	DMEL5SV	Hypertension	BA00-BA04	Phase 2	[11]
VOFOPITANT HYDROCHLORIDE	DMQMYP5	Vomiting	MD90	Phase 2	[158]

Drug(s) Targeting Opioid receptor mu (MOP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[159]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[160]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[161]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[54]
Fentanyl	DM8WAHT	Analgesia	MB40.8	Approved	[162]
Alfentanil	DMVO0UB	Anaesthesia	9A78.6	Approved	[163]
Naloxegol	DML0B41	Opioid-induced constipation	DB32.1	Approved	[164]
Eluxadoline	DMYZ0P1	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[165]
Nalfurafine hcl	DMA9DHW	Uremic pruritus	EC90.10	Approved	[166]
Oxycodone	DMXLKHV	Osteoarthritis	FA00-FA05	Approved	[167]

Drug(s) Targeting Substance-K receptor (TACR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibodutant	DMT67EH	Irritable bowel syndrome	DD91.0	Phase 3	[168]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[169]
Rambazole	DMP2DNS	Psoriasis vulgaris	EA90	Phase 2	[170]
Nepadutant	DMPMF6L	Infantile colics	DD93.1	Phase 1/2	[171]
Saredutant	DMSRJY3	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 3	[172]
CS-003	DM1AEVT	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[173]
FK-224	DM1JUS0	Asthma	CA23	Discontinued in Phase 2	[174]
DNK-333	DM4ZO01	Irritable bowel syndrome	DD91.0	Discontinued in Phase 2	[175]
AVE-5883	DM3P84V	Asthma	CA23	Discontinued in Phase 1/2	[176]
UK-224671	DMDTRJB	Urinary incontinence	MF50.2	Discontinued in Phase 1	[177]

Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxazosin	DM9PLRH	Benign prostatic hyperplasia	GA90	Approved	[178]
Armodafinil	DMGB035	Malignant glioma	2A00.0	Approved	[179]
Alfuzosin	DMZVMKF	Benign prostatic hyperplasia	GA90	Approved	[180]
Moxisylyte	DMFCLYW	Erectile dysfunction	HA01.1	Approved	[181]
Terazosin	DM3JCVS	Benign prostatic hyperplasia	GA90	Approved	[182]
Bunazosin	DM4I8O7	Glaucoma/ocular hypertension	9C61	Approved	[183]
Trimazosin	DM1QLST	Congestive heart failure	BD10	Approved	[184]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[36]
DL-017	DMM8GZT	Hypertension	BA00-BA04	Phase 1	[185]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[186]

Drug(s) Targeting Dopamine transporter (DAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[52]
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[187]
Methylphenidate	DM7SJD6	Attention deficit hyperactivity disorder	6A05.Z	Approved	[188]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[5]
Phenmetrazine	DMXYTN9	Obesity	5B81	Approved	[189]
Ioflupane i-123	DMNARJT	Parkinson disease	8A00.0	Approved	[74]
DEXMETHYLPHENIDATE HYDROCHLORIDE	DM8WBAH	Attention deficit hyperactivity disorder	6A05.Z	Approved	[190]
Altropane	DMO9WDS	Attention deficit hyperactivity disorder	6A05.Z	Approved	[191]
Amitifadine	DMS1X67	Obesity	5B81	Phase 3	[192]
NAV5001	DMRSI1M	Dementia	6D80-6D86	Phase 3	[191]

Drug(s) Targeting 5-HT 4 receptor (HTR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisapride	DMY7PED	Gastroesophageal reflux disease	DA22.Z	Approved	[193]
Tegaserod	DM3XYD1	Irritable bowel syndrome	DD91.0	Approved	[194]
R0-93877	DMM4U9G	Constipation	DD91.1	Approved	[195]
HTF 919	DM78G6F	Constipation	DD91.1	Approved	[196]
Mosapride	DM2VOQ3	N. A.	N. A.	Phase 4	[197]
Renzapride	DM7HQNX	Irritable bowel syndrome	DD91.0	Phase 3	[198]
Lintopride	DMSHGWN	Nausea	MD90	Phase 2	[199]
TD-8954	DM3C9NV	Gastrointestinal disease	DE2Z	Phase 2	[200]
SB-207266A	DM27KFY	Irritable bowel syndrome	DD91.0	Phase 2	[195]
YKP-GI	DM740LV	Constipation	DD91.1	Phase 2	[201]

Drug(s) Targeting 5-HT 3A receptor (HTR3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dolasetron	DMMG26Z	Nausea	MD90	Approved	[202]
Alosetron	DML2A03	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[203]
Tropisetron	DMNSJ7V	Fibromyalgia	MG30.01	Approved	[204]
Palonosetron	DMBHMOX	Nausea	MD90	Approved	[205]
Levetiracetam	DMTGDN8	Epilepsy	8A60-8A68	Approved	[204]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[206]
Cilansetron	DMP0NGX	Irritable bowel syndrome	DD91.0	Phase 3	[207]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[208]
Norcisapride	DMJSKUI	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[209]
YM-114	DML2IXO	Nausea	MD90	Discontinued in Phase 2	[210]

Drug(s) Targeting Histamine H3 receptor (H3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pitolisant	DM8RFNJ	Excessive daytime sleepiness	MG42	Approved	[211]
SUVN-G3031	DM3BO8G	Cognitive impairment	6D71	Phase 3	[212]
JNJ-17216498	DM1GRCU	Narcolepsy	7A20	Phase 2	[213]
GSK239512	DMBJMZC	Alzheimer disease	8A20	Phase 2	[11]
JNJ-39220675	DM0WY3H	Alcohol dependence	6C40.2	Phase 2	[214]
AZD-5213	DMOZ04X	Alzheimer disease	8A20	Phase 2	[215]
Bavisant	DM6CVZ5	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[216]
ABT-288	DM7X54F	Alzheimer disease	8A20	Phase 2	[217]
SAR-110894	DMCLEXM	Alzheimer disease	8A20	Phase 2	[215]
ABT-652	DMLEO2Z	Diabetic neuropathy	8C0Z	Phase 2	[218]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[219]
Haloperidol	DM96SE0	Delirium		Approved	[220]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[221]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[222]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[223]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[224]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[225]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[226]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[227]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[123]

Drug(s) Targeting Muscarinic acetylcholine receptor M3 (CHRM3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolterodine	DMSHPW8	Overactive bladder	GC50.0	Approved	[228]
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[40]
Tiotropium	DMFDC0Q	Chronic obstructive pulmonary disease	CA22	Approved	[229]
Ipratropium	DMFQ320	Obstructive lung disease	CA22.Z	Approved	[230]
Darifenacin	DMWXLYZ	Overactive bladder	GC50.0	Approved	[231]
Methacholine Chloride	DMGS4QH	Asthma	CA23	Approved	[232]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[75]
Solifenacin	DMG592Q	Overactive bladder	GC50.0	Approved	[233]
Methylscopolamine	DM5VWOB	Peptic ulcer	DA61	Approved	[234]
Cevimeline	DMWSMND	Sjogren syndrome	4A43.20	Approved	[235]

Drug(s) Targeting Neuronal acetylcholine receptor alpha-4 (CHRNA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trimethaphan	DMHF4IQ	Aneurysm	BD51.Z	Approved	[236]
Pentolinium	DM38VYQ	Hypotension	BA20-BA21	Approved	[237]
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[238]
ABT-594	DMGMBCW	N. A.	N. A.	Discontinued in Phase 2	[239]
ABT-418	DMNP72I	Alzheimer disease	8A20	Discontinued in Phase 2	[240]
HOMOEPIBATIDINE	DMHP9WV	N. A.	N. A.	Terminated	[238]
Barbituric acid derivative	DM2I19P	Discovery agent	N.A.	Investigative	[241]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	DMDUGZS	Discovery agent	N.A.	Investigative	[242]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	DMDUI8R	Discovery agent	N.A.	Investigative	[242]
BOLDINE	DMMVB5P	Discovery agent	N.A.	Investigative	[243]

Drug(s) Targeting Melanocortin receptor 4 (MC4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methylnaltrexone bromide	DMZTGN2	Opioid-induced constipation	DB32.1	Approved	[244]
Bremelanotide	DM20LIM	Hypoactive sexual desire dysfunction	HA00	Approved	[245]
Setmelanotide	DMPVRN9	Obesity	5B81	Approved	[246]
Amylin	DMWDEN0	N. A.	N. A.	Phase 4	[247]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[244]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[169]
PF-446687	DML38VU	Female sexual arousal dysfunction	HA01.1	Phase 2	[248]
AP-1030	DMBGA35	Metabolic disorder	5C50-5D2Z	Phase 1/2	[148]
PF-07258669	DM3CJ5N	Malnutrition	5B50-5B71	Phase 1	[249]
PT-14	DMYM9JL	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[250]

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[251]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[252]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[253]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[254]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[244]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[255]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[256]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[257]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[258]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[259]

Drug(s) Targeting Adenosine A2a receptor (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[260]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[261]
Regadenoson	DM76VHG	Radionuclide imaging	N.A.	Approved	[74]
Tozadenant	DMATC14	Parkinson disease	8A00.0	Phase 3	[262]
Binodenoson	DMVHF8G	Hypertension	BA00-BA04	Phase 3	[263]
Apadenoson	DMD8QTC	Coronary artery disease	BA80	Phase 3	[264]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[130]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[265]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[266]
BIIB014	DMH7RJ1	Parkinson disease	8A00.0	Phase 2	[267]

Drug(s) Targeting Histamine H1 receptor (H1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[268]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[269]
Azelastine	DMXTMBJ	Allergic conjunctivitis	9A60.02	Approved	[270]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[271]
Cinnarizine	DM7U5QJ	Meniere disease	AB31.0	Approved	[272]
Diphenhydramine	DMKQTBA	Hyperemesis gravidarum		Approved	[270]
Doxepin	DMPI98T	Anxiety		Approved	[273]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[270]
Epinastine	DMX0K3Q	Allergic conjunctivitis	9A60.02	Approved	[274]
Desloratadine	DM56YN7	Allergic rhinitis	CA08.0	Approved	[275]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[5]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[276]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[277]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[278]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[4]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[279]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[280]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[281]
Treximet	DMU54QB	Migraine	8A80	Approved	[11]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[6]

Drug(s) Targeting 5-HT 7 receptor (HTR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[8]
JNJ-18038683	DMV1T59	Major depressive disorder	6A70.3	Phase 2	[282]
AVN-101	DMOGFNI	Cognitive impairment	6D71	Phase 2	[283]
ATI-9242	DM6GKMU	Schizophrenia	6A20	Phase 1	[284]
PMID30124346-Compound-34TABLE4	DM2G3VE	Attention deficit hyperactivity disorder	6A05.Z	Patented	[186]
PMID30124346-Compound-13TABLE4	DMHTJVA	Attention deficit hyperactivity disorder	6A05.Z	Patented	[186]
Carbamide derivative 2	DMW5GI3	N. A.	N. A.	Patented	[285]
4-oxadiazole derivative 1	DMWFHKR	N. A.	N. A.	Patented	[285]
SB-269970	DM8WTGA	Sleep-wake disorder	7A00-7B2Z	Terminated	[286]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[287]

Drug(s) Targeting Muscarinic acetylcholine receptor M5 (CHRM5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Promazine	DMZAL7W	Acute intermittent hepatic porphyria	5C58.11	Approved	[288]
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[40]
Pilocarpine	DMV9ADG	Glaucoma/ocular hypertension	9C61	Approved	[289]
Anisodine	DMNOSWU	Central and peripheral nervous disease	8A04-8E7Z	Approved	[290]
Atropine	DMEN6X7	Organophosphate poisoning	NE6Z	Approved	[291]
Propiverine	DMUWBIJ	Urinary incontinence	MF50.2	Approved	[292]
Umeclidinium	DM4E8O9	Chronic obstructive pulmonary disease	CA22	Approved	[293]
Cimetropium bromide	DMZHPNE	Gastric motility disorder	DA21	Approved	[294]
Butylscopolamine	DMZKXB7	Dysmenorrhea	GA34.3	Approved	[295]
Trospium	DMX6RTG	Overactive bladder	GC50.0	Approved	[86]

Drug(s) Targeting Neuronal acetylcholine receptor beta-2 (CHRNB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[238]
TC-5214	DM8AM60	Palmar hyperhidrosis	EE00.00	Phase 2	[154]
SUVN-911	DMLPBVF	Major depressive disorder	6A70.3	Phase 1	[8]
AZD-9684	DMHA5ME	Thrombosis	DB61-GB90	Discontinued in Phase 2	[296]
ABT-594	DMGMBCW	N. A.	N. A.	Discontinued in Phase 2	[239]
ABT-418	DMNP72I	Alzheimer disease	8A20	Discontinued in Phase 2	[297]
HOMOEPIBATIDINE	DMHP9WV	N. A.	N. A.	Terminated	[238]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	DMDUGZS	Discovery agent	N.A.	Investigative	[242]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	DMDUI8R	Discovery agent	N.A.	Investigative	[242]
BOLDINE	DMMVB5P	Discovery agent	N.A.	Investigative	[243]

Drug(s) Targeting 5-HT 2C receptor (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[115]
Lorcaserin	DMG6OYJ	Obesity	5B81	Approved	[254]
Tramadol	DMRQD04	Osteoarthritis	FA00-FA05	Approved	[298]
Mirtazapine	DML53ZJ	Depression	6A70-6A7Z	Approved	[299]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[300]
Methysergide	DM1EF73	Migraine	8A80	Approved	[301]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[302]
M100907	DM7ZFBA	Sleep-wake disorder	7A00-7B2Z	Phase 3	[303]
SR46349B	DM1ODMR	Primary insomnia	7A00	Phase 3	[304]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[119]

Drug(s) Targeting Neuropeptide Y receptor type 1 (NPY1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NEUROPEPTIDE-Y	DMINQP1	N. A.	N. A.	Phase 2	[305]
H-409/22	DMYJ9CF	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[306]
PD-160170	DMB9Z4C	Heart disease	BA41-BA42	Preclinical	[244]
GI-264879A	DM25N8B	Obesity	5B81	Preclinical	[244]
SR 120819A	DMETDFM	Eating disorder	6B82	Terminated	[307]
BIBP 3226	DMYBR9D	Hypertension	BA00-BA04	Terminated	[308]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2	DMKH8PF	Discovery agent	N.A.	Investigative	[309]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DM4SWQA	Discovery agent	N.A.	Investigative	[309]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2	DMBERSG	Discovery agent	N.A.	Investigative	[309]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2	DM56MOV	Discovery agent	N.A.	Investigative	[309]

Drug(s) Targeting Adenosine A1 receptor (ADORA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[260]
Rolofylline	DMSZPR3	Heart failure	BD10-BD13	Phase 3	[310]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[130]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[266]
SELODENOSON	DMQM3IX	Cardiac arrhythmias	BC9Z	Phase 2	[311]
Apaxifylline	DMQMV9F	Cognitive impairment	6D71	Phase 2	[312]
SLV320	DM867BJ	Heart failure	BD10-BD13	Phase 2	[313]
DTI-0009	DMV84OK	Atrial fibrillation	BC81.3	Phase 2	[311]
Capadenoson	DMYWO62	Atrial fibrillation	BC81.3	Phase 2	[314]
BAY 1067197	DM4JGNH	Heart failure	BD10-BD13	Phase 2	[315]

Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[316]
NAFTOPIDIL	DMQ8R4E	Hypertension	BA00-BA04	Approved	[316]
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[5]
Xatral	DMLHOA0	Benign prostatic hyperplasia	GA90	Approved	[317]
Dutasteride + tamsulosin	DM6P8HU	Benign prostatic hyperplasia	GA90	Phase 3	[11]
Besipirdine	DMLVNTA	Cognitive impairment	6D71	Phase 3	[318]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[36]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[186]
PMID30124346-Compound-LDT66	DMJMTNL	Benign prostatic hyperplasia	GA90	Patented	[186]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[87]

Drug(s) Targeting Melatonin receptor type 1A (MTNR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[319]
Ramelteon	DM7IW9J	Insomnia	7A00-7A0Z	Approved	[320]
Tasimelteon	DMLOQ1V	Insomnia	7A00-7A0Z	Approved	[321]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[322]
LY-156735	DM5IX9M	Anxiety disorder	6B00-6B0Z	Phase 2	[323]
Agomelatine	DMXYA5K	Major depressive disorder	6A70.3	Withdrawn from market	[324]
Luzindole	DMXRJQV	Sleep-wake disorder	7A00-7B2Z	Terminated	[325]
S-20928	DMQDWMJ	Sleep-wake disorder	7A00-7B2Z	Terminated	[326]
GR-133347	DMNRJA0	Anxiety disorder	6B00-6B0Z	Terminated	[327]
GR-131663	DMKAGLV	Anxiety disorder	6B00-6B0Z	Terminated	[328]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Inhibitor	[2]
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Inhibitor	[2]
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Inhibitor	[2]
5-HT 2C receptor (HTR2C)	TTWJBZ5	5HT2C_HUMAN	Inhibitor	[2]
5-HT 3A receptor (HTR3A)	TTPC4TU	5HT3A_HUMAN	Inhibitor	[2]
5-HT 4 receptor (HTR4)	TT07C3Y	5HT4R_HUMAN	Inhibitor	[2]
5-HT 7 receptor (HTR7)	TTO9X1H	5HT7R_HUMAN	Inhibitor	[2]
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[2]
Adenosine A1 receptor (ADORA1)	TTK25J1	AA1R_HUMAN	Inhibitor	[2]
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Inhibitor	[2]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[2]
Adrenergic receptor alpha-1A (ADRA1A)	TTNGILX	ADA1A_HUMAN	Inhibitor	[2]
Adrenergic receptor alpha-1B (ADRA1B)	TTBRKXS	ADA1B_HUMAN	Inhibitor	[2]
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Inhibitor	[2]
Adrenergic receptor alpha-2A (ADRA2A)	TTWG9A4	ADA2A_HUMAN	Inhibitor	[2]
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Inhibitor	[2]
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Inhibitor	[2]
Dopamine D1 receptor (D1R)	TTZFYLI	DRD1_HUMAN	Inhibitor	[2]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Inhibitor	[2]
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Inhibitor	[2]
Dopamine transporter (DAT)	TTVBI8W	SC6A3_HUMAN	Inhibitor	[2]
Endothelin A receptor (EDNRA)	TTKRD0G	EDNRA_HUMAN	Inhibitor	[2]
Gastrin/cholecystokinin type B receptor (CCKBR)	TTVFO0U	GASR_HUMAN	Inhibitor	[2]
Glucocorticoid receptor messenger RNA (GCR mRNA)	TTOZRK6	GCR_HUMAN	Inhibitor	[2]
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Inhibitor	[2]
Histamine H2 receptor (H2R)	TTQHJ1K	HRH2_HUMAN	Inhibitor	[2]
Histamine H3 receptor (H3R)	TT9JNIC	HRH3_HUMAN	Inhibitor	[2]
Melanocortin receptor 4 (MC4R)	TTD0CIQ	MC4R_HUMAN	Inhibitor	[2]
Melatonin receptor type 1A (MTNR1A)	TT0WAIE	MTR1A_HUMAN	Inhibitor	[2]
Muscarinic acetylcholine receptor M1 (CHRM1)	TTZ9SOR	ACM1_HUMAN	Inhibitor	[3]
Muscarinic acetylcholine receptor M2 (CHRM2)	TTYEG6Q	ACM2_HUMAN	Inhibitor	[2]
Muscarinic acetylcholine receptor M3 (CHRM3)	TTQ13Z5	ACM3_HUMAN	Inhibitor	[2]
Muscarinic acetylcholine receptor M4 (CHRM4)	TTQ3JTF	ACM4_HUMAN	Inhibitor	[2]
Muscarinic acetylcholine receptor M5 (CHRM5)	TTH18TF	ACM5_HUMAN	Inhibitor	[2]
Neuronal acetylcholine receptor alpha-4 (CHRNA4)	TT4H1MQ	ACHA4_HUMAN	Inhibitor	[2]
Neuronal acetylcholine receptor beta-2 (CHRNB2)	TT5KPZR	ACHB2_HUMAN	Inhibitor	[2]
Neuropeptide Y receptor type 1 (NPY1R)	TTRK9JT	NPY1R_HUMAN	Inhibitor	[2]
Neurotensin receptor type 1 (NTSR1)	TTTUMEP	NTR1_HUMAN	Inhibitor	[2]
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[2]
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Inhibitor	[2]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[2]
Substance-K receptor (TACR2)	TTYO0A3	NK2R_HUMAN	Inhibitor	[2]
Substance-P receptor (TACR1)	TTZPO1L	NK1R_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 289).
• [2] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [3] Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
• [4] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [7] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [12] Neurotensin inversely modulates maternal aggression. Neuroscience. 2009 Feb 18;158(4):1215-23.
• [13] Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic. J Med Chem. 2010 Jun 24;53(12):4623-32.
• [14] Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem. 2008 Aug;8(6):603-17.
• [15] Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol. 2001 Dec;60(6):1392-8.
• [16] Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy. J Med Chem. 2009 Apr 9;52(7):1803-13.
• [17] Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus. Mol Pharmacol. 2003 Aug;64(2):421-9.
• [18] [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol Pharmacol. 1995 May;47(5):1050-6.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 309).
• [20] Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensi... Bioorg Med Chem. 2008 Oct 15;16(20):9359-68.
• [21] Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology. 2009 Jan;34(2):509-21.
• [22] Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8.
• [23] Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 April 24; 94(8): 1107-1115.
• [24] Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7.
• [25] Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9.
• [26] The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98.
• [27] Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gen... Biol Pharm Bull. 2010;33(2):216-22.
• [28] Selective action of a CCK-B/gastrin receptor antagonist, S-0509, on pentagastrin-, peptone meal- and beer-stimulated gastric acid secretion in dogs. Aliment Pharmacol Ther. 2000 Apr;14(4):479-88.
• [29] CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs. Scand J Gastroenterol. 2004 Sep;39(9):886-90.
• [30] Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem. 2007; 7(12): 1211-1231.
• [31] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [32] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [33] alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
• [34] Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
• [35] Clinical pipeline report, company report or official report of Klus Pharma
• [36] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [37] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [38] Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
• [39] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [40] Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
• [41] 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
• [42] The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 rec... Psychopharmacology (Berl). 2007 Oct;194(3):347-59.
• [43] Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2972-6.
• [44] cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
• [45] Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14.
• [46] Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82.
• [47] Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
• [48] Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5.
• [49] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [50] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [51] Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
• [52] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [53] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [54] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [55] Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
• [56] Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
• [57] Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
• [58] Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
• [59] Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
• [60] Clinical pipeline report, company report or official report of Lundbeck.
• [61] A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
• [62] Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
• [63] trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
• [64] Clinical pipeline report, company report or official report of Lundbeck
• [65] Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33.
• [66] Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
• [67] Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
• [68] Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
• [69] Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
• [70] Pfizer. Product Development Pipeline. March 31 2009.
• [71] Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
• [72] Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.
• [73] Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
• [74] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [75] Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
• [76] Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
• [77] The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
• [78] Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
• [79] Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
• [80] Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
• [81] Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
• [82] Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
• [83] Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
• [84] Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
• [85] Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
• [86] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [87] 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
• [88] An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
• [89] Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
• [90] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [91] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [92] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [93] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [94] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [95] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [96] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [97] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [98] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [99] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
• [100] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [101] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [102] Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6086-90.
• [103] Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J Biol Chem. 2000Jun 23;275(25):19041-9.
• [104] Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9.
• [105] Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1721-7.
• [106] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [107] Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
• [108] Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
• [109] Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
• [110] Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
• [111] Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
• [112] Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
• [113] Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
• [114] New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
• [115] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [116] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [117] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [118] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [119] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [120] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [121] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [122] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [123] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [124] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [125] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [126] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [127] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [128] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [129] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [130] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [131] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [132] 2011 Pipeline of Can-Fite BioPharm.
• [133] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [134] Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
• [135] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [136] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [137] Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
• [138] Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
• [139] Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
• [140] Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
• [141] Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
• [142] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [143] beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
• [144] beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
• [145] Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7.
• [146] Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24.
• [147] Clinical pipeline report, company report or official report of FemmePharma.
• [148] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [149] Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S43-9.
• [150] Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists. J Med Chem. 2002 Dec 5;45(25):5415-8.
• [151] In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.
• [152] Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46.
• [153] Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44.
• [154] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [155] Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498.
• [156] Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234.
• [157] A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
• [158] Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenicchemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jun;10(6):549-58.
• [159] Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
• [160] Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
• [161] Clinical pipeline report, company report or official report of signaturerx.
• [162] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [163] Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
• [164] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [165] Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
• [166] Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
• [167] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
• [168] Antagonist profile of ibodutant at the tachykinin NK2 receptor in guinea pig isolated bronchi. Eur J Pharmacol. 2013 Nov 15;720(1-3):180-5.
• [169] Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
• [170] Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. Eur J Pharmacol. 2005 Jun 1;516(2):104-11.
• [171] Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
• [172] Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol. 2009 May 1;77(9):1522-30.
• [173] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [174] Effects of FK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerv... J Pharmacol Exp Ther. 1992 Jul;262(1):403-8.
• [175] Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J. 2004 Jan;23(1):76-81.
• [176] Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med. 2007 Mar 1;175(5):450-7.
• [177] Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human. Xenobiotica. 2000 Jun;30(6):627-42.
• [178] The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
• [179] Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
• [180] Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
• [181] Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
• [182] Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
• [183] Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
• [184] The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
• [185] Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
• [186] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [187] Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
• [188] Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
• [189] Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
• [190] Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
• [191] Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
• [192] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
• [193] Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
• [194] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [195] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [196] 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
• [197] The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
• [198] Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
• [199] The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
• [200] The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
• [201] A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.
• [202] Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
• [203] Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
• [204] Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
• [205] Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
• [206] Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
• [207] Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
• [208] Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
• [209] mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
• [210] Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
• [211] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [212] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [213] Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61.
• [214] JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41.
• [215] SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
• [216] Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.
• [217] A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71.
• [218] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225)
• [219] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [220] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [221] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [222] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [223] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [224] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [225] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [226] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [227] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [228] Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
• [229] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [230] Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
• [231] M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
• [232] Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
• [233] Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
• [234] Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
• [235] Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.
• [236] Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40.
• [237] Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6.
• [238] Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
• [239] The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 1999 Dec 16;10(18):3909-13.
• [240] (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):319-28.
• [241] Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.
• [242] Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
• [243] Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72.
• [244] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [245] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [246] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [247] Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
• [248] Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
• [249] Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss. J Med Chem. 2023 Mar 9;66(5):3195-3211.
• [250] The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.
• [251] Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
• [252] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [253] Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
• [254] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [255] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [256] Company report (Gwpharm)
• [257] Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
• [258] Clinical pipeline report, company report or official report of Bird Rock Bio.
• [259] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [260] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [261] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [262] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
• [263] Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
• [264] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
• [265] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [266] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [267] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
• [268] Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
• [269] Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
• [270] Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
• [271] Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
• [272] Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
• [273] Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
• [274] Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
• [275] Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
• [276] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [277] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [278] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [279] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [280] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [281] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [282] Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
• [283] AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
• [284] Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
• [285] Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
• [286] [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
• [287] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [288] Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
• [289] Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
• [290] Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
• [291] Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
• [292] Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
• [293] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
• [294] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [295] Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
• [296] Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51.
• [297] Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44.
• [298] The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
• [299] Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
• [300] Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
• [301] Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
• [302] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [303] Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
• [304] SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
• [305] 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
• [306] In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25.
• [307] SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995 Apr 3;362(2):192-6.
• [308] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 305).
• [309] Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
• [310] Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
• [311] Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
• [312] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
• [313] Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
• [314] A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
• [315] Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.
• [316] Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
• [317] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [318] Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
• [319] The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8.
• [320] MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
• [321] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
• [322] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288).
• [323] Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25.
• [324] Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68.
• [325] Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988 Sep;246(3):902-10.
• [326] Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. J Pineal Res. 1998 Oct;25(3):172-6.
• [327] US patent application no. 5,151,446, Substituted 2-amidotetralins as melatonin agonists and antagonists.
• [328] Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol. 1999 Oct 15;382(3):157-66.